... a platelet count pattern in patient with bladder cancer underwent Gemcitabine and Cisplatin (GC) therapy and pembrolizumab monotherapy. Conclusion: This case underscores the need for a diverse perspective on platelet behavior in clinical settings. [email protected] 24 04 2024 25 09...

...Tadahiro Kuribayashi; Keiichi Fujiwara; Kiriko Onishi; Sho Mitsumune; Yuki Takigawa; Hiromi Watanabe; Kenichiro Kudo; Akiko Sato; Ken Sato; Masashi Kitagawa; Kosuke Ota; Yoko Shinno; Takuo Shibayama A 69-year-old man with refractory lung adenocarcinoma was treated with gemcitabine and vinorelbine...

..., with only 1–2% of the patients reaching the 5-year survival follow-up. Current advances in systemic treatment with gemcitabine regimens, specifically polychemotherapy with gemcitabine plus nab-paclitaxel or other multidrug regimens such as FOLFIRINOX in the first line, have improved disease control over...

...Jalal Baig; Mohammad Shokouh-Amiri; Juliana Chan; Rozina Chowdhery; Samaya Danthurthy; Neeta K. Venepalli Gemcitabine is widely utilized in the treatment of pancreatic, ovarian, and non small cell lung cancers. Gemcitabine is associated with a wide spectrum of lung toxicities, ranging from dyspnea...

... (gemcitabine and cisplatin). Following chemotherapy, enlarged pelvic lymph nodes were noted, and extremely aggressive local progression of the bladder tumor was confirmed. The patient ultimately died 6 months after his initial visit to our hospital. [email protected] 30 07 2018 30 07...

...Salma Alam; Chidi Illo; Yuk Ting Ma; Pankaj Punia Gemcitabine is not considered a cardiotoxic agent generally; so far only very few case reports have been reported in the literature on different aspects of cardiac side effects. Here we report a case series of 3 patients who developed congestive...

...Adarsh Ravishankar; Sean S. Park; Kenneth R. Olivier; Kimberly S. Corbin Gemcitabine-induced radiation recall (GIRR) is a phenomenon wherein the administration of gemcitabine induces an inflammatory reaction within an area of prior radiation. We present the case of a 39-year-old female patient...

... differentiated pancreatic ductal adenocarcinoma. Another biopsy was performed in the right iliac wing. Pathological examination with immunohistochemistry confirmed the diagnosis of bone metastasis from clear cell renal cell carcinoma. The patient was treated with a combination of gemcitabine, sunitinib...

... of Vater of an initially diagnosed intestinal subtype who developed pulmonary metastases 2 months after adjuvant gemcitabine chemotherapy and, subsequently, liver metastases. Palliative combination chemotherapy with standard regimens for intestinal-type adenocarcinoma (FOLFOX and FOLFIRI) failed. However...

... regimens, the recommended treatment for pancreatic cancer patients with poor PS is gemcitabine monotherapy. We report the case of a 79-year-old female with pancreatic adenocarcinoma metastatic to the lungs, with multiple comorbidities and an Eastern Cooperative Oncology Group PS of 3, who achieved a rapid...

... with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy regimen consisting of 2 cycles of nab -paclitaxel plus gemcitabine...

...Koichi Suyama; Masafumi Ikeda; Eiichiro Suzuki; Motohiro Kojima; Shuichi Mitsunaga; Satoshi Shimizu; Izumi Ohno; Hideaki Takahashi; Hiroyuki Okuyama; Akiko Kuwahara; Takuji Okusaka; Junji Furuse The tumor shrinkage effect of gemcitabine is considered to be limited in cases of advanced gallbladder...

... with gemcitabine and oxaliplatin (GEMOX regimen) achieved a complete response without relapse five years after discontinuation of chemotherapy. This exceptional case raises the question of clinical trials specifically designed for patients with HCC in non-cirrhotic liver. Fibrolamellar hepatocellular carcinoma...

... to initiating treatment, a portacath was surgically implanted. Subsequently, the patient received a weekly dose of 1,000 mg/m 2 gemcitabine combined with 2,000 mg/m 2 high-dose 5-fluorouracil as a 24-hour infusion for palliative treatment. As the patient was suffering from a stenosis of the ductus hepaticus...

...Pashtoon Murtaza Kasi Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening complication of gemcitabine treatment. Since the approval of this nucleoside analog for the treatment of pancreatic cancer by the FDA in 1996, reported incidence varies from 0.015 to 1.4%. The classic...

... neuroimaging findings. We report a case of a 74-year-old woman receiving adjuvant gemcitabine chemotherapy as monotherapy for a stage IIa pancreatic adenocarcinoma, who developed posterior reversible encephalopathy syndrome. © 2011 S. Karger AG, Basel 2011 Open Access License / Drug Dosage / Disclaimer...

...Kazuhito Mita; Hideto Ito; Masato Fukumoto; Ryo Murabayashi; Masashi Nabetani; Kazuya Koizumi; Takashi Hayashi Background: The aim of this study was to investigate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Patients...